ライフサイエンスコーパス: endothelial nitric oxide synthase

1 e not dependent upon endothelial caveolae or endothelial nitric oxide synthase.

2 attenuation of the vasoprotective effects of endothelial nitric oxide synthase.

3 bility and superoxide generated by uncoupled endothelial nitric oxide synthase.

4 ectable in mice with a genetic deficiency of endothelial nitric oxide synthase.

5 proangiogenic mediators VEGF receptor 2 and endothelial nitric oxide synthase.

6 related increases in shear and activation of endothelial nitric oxide synthase.

7 din-1 and inhibited S1177 phosphorylation of endothelial nitric oxide synthase.

8 minished VEGF-mediated activation of Akt and endothelial nitric-oxide synthase.

9 n C57BL/6J mice but not in mice deficient in endothelial nitric-oxide synthase.

10 tion of both Thr-172 of AMPK and Ser-1177 of endothelial nitric oxide synthase, a downstream enzyme o

11 mice showed markedly decreased expression of endothelial nitric oxide synthase, a well-known mediator

12 Inhibition of endothelial nitric oxide synthase abolished globular adi

13 Combined indomethacin and inhibition of endothelial nitric oxide synthase abolished the effects

14 ice, we tested the hypothesis that a lack of endothelial nitric oxide synthase accelerates renal inju

15 is because of loss of insulin-stimulated Akt/endothelial nitric oxide synthase activation and angiote

16 ndothelial cells, SR-BI mediates HDL-induced endothelial nitric oxide synthase activation and prolife

17 se data describe a new mechanism for reduced endothelial nitric oxide synthase activation during rena

18 etworks, reactive oxygen species production, endothelial nitric oxide synthase activation, and cGMP p

19 nt of circulating angiogenic cells, enhanced endothelial nitric oxide synthase activation, and increa

20 red by approximately 40% with respect to Akt/endothelial nitric oxide synthase activation, and leukoc

21 helial sodium channel activation, attenuated endothelial nitric oxide synthase activation, increased

22 thelin B receptor and consequently decreased endothelial nitric oxide synthase activation.

23 proinflammatory polarization, restoration of endothelial nitric oxide synthase activation.

24 line in endothelial nitric oxide release and endothelial nitric oxide synthase activity and increased

25 MPs from patients with OSA reduced endothelial nitric oxide synthase activity and nitric ox

26 wild-type mice coincident with reduced liver endothelial nitric oxide synthase activity and NO conten

27 Statins improve endothelial nitric oxide synthase activity and vascular

28 accepted that diabetes mellitus (DM) impairs endothelial nitric oxide synthase activity as well as en

29 ecovery, vascular and capillary density, and endothelial nitric oxide synthase activity were signific

30 ow recovery, vascular and capillary density, endothelial nitric oxide synthase activity, and were ass

31 rdiovascular homeostasis, along with reduced endothelial nitric oxide synthase activity, endothelial

32 tionality via nitrite reduction and red cell endothelial nitric oxide synthase activity, potentially

33 ein expressions of nuclear factor kappaB and endothelial nitric oxide synthase/Akt/inducible nitric o

34 an increase in capillary/arteriole density, endothelial nitric oxide synthase/Akt/vascular endotheli

35 recovery in obese type 2 diabetic mice by an endothelial nitric oxide synthase/Akt/vascular endotheli

36 tion factor Kruppel-like factor 2 as well as endothelial nitric oxide synthase, along with significan

37 f PI3K downstream targets, including Akt and endothelial nitric oxide synthase, although incremental

38 ey endothelial signaling proteins--including endothelial nitric oxide synthase, AMP-activated protein

39 L(Healthy) were observed after inhibition of endothelial nitric oxide synthase and after delipidation

40 Because endothelial nitric oxide synthase and Bcl-2 activities a

41 pairment of agonist-stimulated activation of endothelial nitric oxide synthase and cGMP production.

42 kinase and its downstream effectors CD36 and endothelial nitric oxide synthase and cyclooxygenase-2 a

43 ocosahexaenoic acid increased phosphorylated endothelial nitric oxide synthase and endothelial nitric

44 Additionally, endothelial nitric oxide synthase and extracellular sign

45 SIRT1-regulated Akt, endothelial nitric oxide synthase and GLUT4 levels were

46 ed heart failure in part via upregulation of endothelial nitric oxide synthase and increased nitric o

47 ase/Akt pathway to inhibit the activation of endothelial nitric oxide synthase and metabolic actions.

48 ates 2 critical antiatherosclerotic enzymes, endothelial nitric oxide synthase and prostacyclin synth

49 activated protein kinase (AMPK) and requires endothelial nitric oxide synthase and soluble guanylyl c

50 ally reduced by inhibition or elimination of endothelial nitric oxide synthase and that the vasodilat

51 n (activation) of Protein kinase B (Akt) and endothelial nitric oxide synthase and the phosphorylatio

52 n (activation) of Protein kinase B (Akt) and endothelial nitric oxide synthase and the phosphorylatio

53 he expression of KLF2 and the KLF2-regulated endothelial nitric oxide synthase and thrombomodulin at

54 Expression of proangiogenic proteins phospho-endothelial nitric oxide synthase and vascular endotheli

55 tream signaling targets of VEGFR2, including endothelial nitric-oxide synthase and soluble guanylate

56 shear stress-induced signaling, because Akt, endothelial nitric oxide synthase, and extracellular reg

57 or CD31, vascular endothelial growth factor, endothelial nitric oxide synthase, and hypoxia-inducible

58 ed endothelial cell levels of phosphorylated endothelial nitric oxide synthase, and of nitrates and n

59 ing phosphodiesterase type 5, phosphorylated endothelial nitric oxide synthase, and phosphorylated va

60 ic AMP/protein kinase A signaling machinery, endothelial nitric oxide synthase, and Rac1.

61 sed the mRNA and protein expression of KLF2, endothelial nitric oxide synthase, and thrombomodulin.

62 activation of AMP-activated protein kinase, endothelial nitric oxide synthase, and vascular endothel

63 d from shear stress-dependent stimulation of endothelial nitric oxide synthase at the remote site of

64 bition of nitric oxide/nitrite generation by endothelial nitric oxide synthase at the remote site or

65 taII-dependent inhibitory phosphorylation of endothelial nitric oxide synthase at Thr-495, leading to

66 Inhibition of endothelial nitric oxide synthase attenuated flow augmen

67 roup 3, whereas messenger RNA expressions of endothelial nitric oxide synthase, Bcl-2, interleukin-10

68 trosation was associated with increased Cav1-endothelial nitric oxide synthase binding in response to

69 on of vascular endothelial growth factor and endothelial nitric oxide synthase, but the expression of

70 (HUVEC), resulting in the phosphorylation of endothelial nitric oxide synthase, cell migration, and t

71 product dihydrobiopterin (BH2), which lacks endothelial nitric oxide synthase cofactor activity.

72 The endothelial nitric oxide synthase cofactor tetrahydrobio

73 The endothelial nitric oxide synthase cofactor tetrahydrobio

74 on, obesity-induced perturbations in cardiac endothelial nitric oxide synthase, connexin-43, and mark

75 Whereas both inducible and endothelial nitric oxide synthase contributed to nitric

76 vascular homocysteine, is a key regulator of endothelial nitric oxide synthase coupling and nitric ox

77 iated virus (AAV) expressing cKL to diabetic endothelial nitric oxide synthase-deficient mice or alph

78 anol-mediated suppression of EPC biology was endothelial nitric oxide synthase-dependent because endo

79 Neuregulin production, endothelial nitric oxide synthase dimerization, and Bcl-

80 tetrahydrobiopterin concentrations, ratio of endothelial nitric oxide synthase dimers/monomers, and n

81 upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase downregulation, and re

82 ation and high arginase activity, leading to endothelial nitric oxide synthase dysfunction.

83 including phosphorylated STAT3 (p-STAT3) and endothelial nitric oxide synthase (e-NOS).

84 al dysfunction with ageing via modulation of endothelial nitric oxide synthase (eNOS) acetylation/act

85 ion, IRAK1 degradation, RONS generation, and endothelial nitric oxide synthase (eNOS) activation (as

86 ers membrane-initiated signals, resulting in endothelial nitric oxide synthase (eNOS) activation and

87 delivery, and it was associated with blunted endothelial nitric oxide synthase (eNOS) activation in s

88 tions of Cav1 and NOS3, we show that chronic endothelial nitric oxide synthase (eNOS) activation seco

89 oproteins, aortic pathology, aortic Akt1 and endothelial nitric oxide synthase (eNOS) activities, imm

90 adrenergic receptor (AR) activation promotes endothelial nitric oxide synthase (eNOS) activity and NO

91 Caveolin-1 exerts a tonic inhibition of endothelial nitric oxide synthase (eNOS) activity.

92 factor signaling, which can lead to reduced endothelial nitric oxide synthase (eNOS) activity; the e

93 AMD3100 upregulated BM levels of endothelial nitric oxide synthase (eNOS) and 2 targets o

94 tary wheel running (VWR) on the abundance of endothelial nitric oxide synthase (eNOS) and extracellul

95 Both endothelial nitric oxide synthase (eNOS) and inducible n

96 protects the heart, but it is apparent that endothelial nitric oxide synthase (eNOS) and nitric oxid

97 asculogenesis and angiogenesis) we evaluated endothelial nitric oxide synthase (eNOS) and phosphoryla

98 In vitro, Akt1 preferentially phosphorylates endothelial nitric oxide synthase (eNOS) and promotes NO

99 We tested this concept and the roles of endothelial nitric oxide synthase (eNOS) and Src activat

100 t Cav-1 deficiency induced the activation of endothelial nitric oxide synthase (eNOS) and the generat

101 red pericytes were used, and intervened with endothelial nitric oxide synthase (eNOS) antagonist L-NN

102 Deficits in nitric oxide production by endothelial nitric oxide synthase (eNOS) are associated

103 Kruppel-like factor 2 (KLF2) and endothelial nitric oxide synthase (eNOS) are fluid shear

104 e (AMPK), with subsequent phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser-633 and

105 a vasorelaxing agent that acts downstream of endothelial nitric oxide synthase (eNOS) by directly act

106 ty of substrate and/or necessary co-factors, endothelial nitric oxide synthase (eNOS) can generate NO

107 X receptor-alpha (RXRA) chr9:136355885+ and endothelial nitric oxide synthase (eNOS) chr7:150315553+

108 Endothelial nitric oxide synthase (eNOS) deficiency may

109 However, the functional significance of endothelial nitric oxide synthase (eNOS) expressed in he

110 , abacavir, and AZT) significantly decreased endothelial nitric oxide synthase (eNOS) expression and

111 mice was altered and associated with reduced endothelial nitric oxide synthase (eNOS) expression and

112 firmed in IRKO mice, consistent with reduced endothelial nitric oxide synthase (eNOS) expression in b

113 Endothelial nitric oxide synthase (eNOS) expression was

114 Endothelial nitric oxide synthase (eNOS) expression was

115 tumors, Ad-VEGF-A(164) strikingly increased endothelial nitric oxide synthase (eNOS) expression.

116 -VEGFR-2, cyclooxygenase (COX)-1, COX-2, and endothelial nitric oxide synthase (eNOS) expressions as

117 nary vasodilation is impaired due to loss of endothelial nitric oxide synthase (eNOS) function.

118 Polymorphisms in the human endothelial nitric oxide synthase (eNOS) gene (NOS3) hav

119 Dysfunction of endothelial nitric oxide synthase (eNOS) has been implic

120 Endothelial nitric oxide synthase (eNOS) has been shown

121 the wall shear stress-induced activation of endothelial nitric oxide synthase (eNOS) in an endotheli

122 l of green tea (GT) to improve uncoupling of endothelial nitric oxide synthase (eNOS) in diabetic con

123 The role of endothelial nitric oxide synthase (eNOS) in forming nati

124 hich nanomolar resveratrol rapidly activates endothelial nitric oxide synthase (eNOS) in human umbili

125 Using this method, we demonstrated that endothelial nitric oxide synthase (eNOS) in lymphatic en

126 ing via phosphatidylinositol 3-kinase/Akt to endothelial nitric oxide synthase (eNOS) in the vasculat

127 Whereas endothelial nitric oxide synthase (eNOS) inhibition had

128 ylcholine, which was completely abolished by endothelial nitric oxide synthase (eNOS) inhibitor N(G)-

129 Endothelial nitric oxide synthase (eNOS) is a critical m

130 Endothelial nitric oxide synthase (eNOS) is an important

131 Endothelial nitric oxide synthase (eNOS) is critical in

132 Because endothelial nitric oxide synthase (eNOS) is involved in

133 e that, in glomerular mesangial cells (MCs), endothelial nitric oxide synthase (eNOS) is uncoupled up

134 ss podocyte VEGF-A on the renal phenotype of endothelial nitric oxide synthase (eNOS) knockout mice.

135 in which post-translational modifications of endothelial nitric oxide synthase (eNOS) lead to impaire

136 eduction in apoptosis and an upregulation of endothelial nitric oxide synthase (eNOS) levels in ische

137 with sCD40L showed significant reductions of endothelial nitric oxide synthase (eNOS) mRNA and protei

138 All three kinases phosphorylate endothelial nitric oxide synthase (eNOS) on serine (S) 1

139 Rho kinase (RhoK) / protein kinase B (AKT) / endothelial nitric oxide synthase (eNOS) pathways was an

140 nsin (ANG)-(1-7)-induced vasodilator effect, endothelial nitric oxide synthase (eNOS) phosphorylation

141 Ranolazine's effects on endothelial nitric oxide synthase (eNOS) phosphorylation

142 xpectedly, we observed 1.7-fold higher basal endothelial nitric oxide synthase (eNOS) phosphorylation

143 thelial growth factor (VEGF)-induced Akt and endothelial nitric oxide synthase (eNOS) phosphorylation

144 Erk phosphorylation and shear stress-induced endothelial nitric oxide synthase (eNOS) phosphorylation

145 T signaling cascade and subsequent increased endothelial nitric oxide synthase (eNOS) phosphorylation

146 y CAP exposure suppressed insulin-stimulated endothelial nitric oxide synthase (eNOS) phosphorylation

147 and this was associated with an increase in endothelial nitric oxide synthase (eNOS) phosphorylation

148 II sensitivity and hypertension by impairing endothelial nitric oxide synthase (eNOS) phosphorylation

149 Endothelial nitric oxide synthase (eNOS) plays a central

150 jects prospectively genotyped for the Asp298 endothelial nitric oxide synthase (eNOS) polymorphism an

151 ing upon contact with blood to interact with endothelial nitric oxide synthase (eNOS) present in bloo

152 ed endothelial nitric oxide synthase (PeNOS)/endothelial nitric oxide synthase (eNOS) ratio was measu

153 The molecular mechanisms of endothelial nitric oxide synthase (eNOS) regulation of m

154 Indeed, RNAi of p47phox inhibited endothelial nitric oxide synthase (eNOS) serine 1179 pho

155 at this process is inhibited by the PI3K/Akt/endothelial nitric oxide synthase (eNOS) signaling pathw

156 hepatic stellate cell contraction), and the endothelial nitric oxide synthase (eNOS) signaling pathw

157 CRP antagonizes endothelial nitric oxide synthase (eNOS) through process

158 ility to macromolecules via translocation of endothelial nitric oxide synthase (eNOS) to cytosol and

159 nthesis, dysregulated l-arginine metabolism, endothelial nitric oxide synthase (eNOS) uncoupling and

160 Vascular superoxide (O2(-)) and endothelial nitric oxide synthase (eNOS) uncoupling were

161 Endothelial dysfunction, which is caused by endothelial nitric oxide synthase (eNOS) uncoupling, is

162 Endothelin-1 is known to stimulate endothelial nitric oxide synthase (eNOS) via the endothe

163 nd brain in organ specific manners; however, endothelial nitric oxide synthase (eNOS) was not signifi

164 PPARdelta agonist GW501516 on uncoupling of endothelial nitric oxide synthase (eNOS) were determined

165 Inhibition of endothelial nitric oxide synthase (eNOS) with the specif

166 AKT, AMP-dependent kinase (AMPK), and endothelial nitric oxide synthase (eNOS)(s1179) phosphor

167 genes such as Kruppel-like factor 2 (Klf2), endothelial nitric oxide synthase (eNOS), and bone morph

168 th reduced Kruppel-like factor (KLF)2, KLF4, endothelial nitric oxide synthase (eNOS), and thrombomod

169 (VCAM-1), nuclear factor kappaB (NF-kappaB), endothelial nitric oxide synthase (eNOS), B-cell leukemi

170 n contributes to AMPK-mediated activation of endothelial nitric oxide synthase (eNOS), enhanced level

171 lpha-induced signaling cascade that involves endothelial nitric oxide synthase (eNOS), JNK3, and MAPK

172 ition, liver samples were obtained to assess endothelial nitric oxide synthase (eNOS), phosphorylated

173 tio and upregulated the expression of aortic endothelial nitric oxide synthase (eNOS), phosphorylated

174 Instead, expression of endothelial nitric oxide synthase (eNOS), which generate

175 Endothelial nitric oxide synthase (eNOS)-mediated NO pro

176 mall intestine via the vasodilatory molecule endothelial nitric oxide synthase (eNOS).

177 uced inflammation through phosphorylation of endothelial nitric oxide synthase (eNOS).

178 and requires nitric oxide (NO) derived from endothelial nitric oxide synthase (eNOS).

179 obiopterin (BH4) is an essential cofactor of endothelial nitric oxide synthase (eNOS).

180 tein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS).

181 Instead, it increased tissue expression of endothelial nitric oxide synthase (eNOS).

182 tase 2A (PP2A) association directly with the endothelial nitric oxide synthase (eNOS)/Akt/Hsp90 compl

183 type through upregulating proteins including endothelial nitric oxide synthase (eNOS)/inducible nitri

184 othelin-1, endothelin-1 receptor type A, and endothelial nitric oxide synthase (eNOS)], pro-inflammat

185 de spanning the calmodulin binding domain of endothelial nitric oxide synthase (eNOS, 494-513) and a

186 Activation of endothelial nitric oxide synthase (eNOS, NOS3, or NOS II

187 ion of PPARdelta might prevent uncoupling of endothelial nitric oxide synthase (eNOS, P<0.05, n=6-9).

188 Endothelial dysfunction, including decreased endothelial nitric-oxide synthase (eNOS) activity and lo

189 Endothelial nitric-oxide synthase (eNOS) and its bioacti

190 ed H-Ras mediates VEGF-induced activation of endothelial nitric-oxide synthase (eNOS) and migratory r

191 ontrolling the stability and activity of the endothelial nitric-oxide synthase (eNOS) and that Cavin-

192 educed insulin-stimulated phosphorylation of endothelial nitric-oxide synthase (eNOS) at Ser(1177) an

193 Kallistatin increased endothelial nitric-oxide synthase (eNOS) expression and

194 n of Kruppel-like factor 2 (KLF2), increased endothelial nitric-oxide synthase (eNOS) expression, and

195 Recent evidence suggests that blunted Cav-1/endothelial nitric-oxide synthase (eNOS) interaction, wh

196 Endothelial nitric-oxide synthase (eNOS) is a critical r

197 ing of NO production from NADPH oxidation by endothelial nitric-oxide synthase (eNOS) is enhanced in

198 sis of NO in sinusoidal endothelial cells by endothelial nitric-oxide synthase (eNOS) is regulated in

199 ies have shown that the acute stimulation of endothelial nitric-oxide synthase (eNOS) mRNA transcript

200 Endothelial nitric-oxide synthase (eNOS) plays a central

201 n important post-translational mechanism for endothelial nitric-oxide synthase (eNOS) regulation.

202 itions of oxidative stress generally and for endothelial nitric-oxide synthase (eNOS) specifically.

203 arginine (ADMA) induces the translocation of endothelial nitric-oxide synthase (eNOS) to the mitochon

204 maintains endothelial function by targeting endothelial nitric-oxide synthase (eNOS) to the plasma m

205 Endothelial nitric-oxide synthase (eNOS) uncoupling and

206 we demonstrate that, in MCs, Ang II induces endothelial nitric-oxide synthase (eNOS) uncoupling with

207 Endothelial nitric-oxide synthase (eNOS) utilizes l-argi

208 PI3K/Akt pathway to reduce the activation of endothelial nitric-oxide synthase (eNOS).

209 he plasma membrane Ca(2+)-ATPase (PMCA), and endothelial nitric-oxide synthase (eNOS).

210 factors in the angiogenesis pathway (Akt and endothelial nitric oxide synthase [eNOS]) are activated.

211 lved intrahepatic vasoactive pathways (e.g., endothelial nitric oxide synthase [eNOS], Rho-kinase, an

212 artery endothelial cells in vitro increased endothelial nitric oxide synthase expression and activat

213 flow and regulates EC function by increasing endothelial nitric oxide synthase expression and inhibit

214 A decrease in endothelial nitric oxide synthase expression levels was

215 uent regulation of Kruppel-like factor 2 and endothelial nitric oxide synthase expression represents

216 criptional activity and laminar flow-induced endothelial nitric oxide synthase expression through ERK

217 cally, loss of Nox4 resulted in reduction of endothelial nitric oxide synthase expression, nitric oxi

218 irectly phosphorylated ERK5 S496 and reduced endothelial nitric oxide synthase expression.

219 odulated vascular permeability by increasing endothelial nitric-oxide synthase expression and by down

220 ) expression, apoptosis, and increased eNOS (endothelial nitric oxide synthase) expression.

221 The latter hampered the detachment of endothelial nitric oxide synthase from caveolin-1, leadi

222 thological signaling and enhanced myocardial endothelial nitric oxide synthase function and nitric ox

223 sion) of epigenetic (5-mC, DNMTs), vascular (endothelial nitric oxide synthase), glial (connexin-43,

224 ty of endogenous nitric oxide and upregulate endothelial nitric oxide synthase, have been used to pre

225 methylarginines and subsequent ADMA-mediated endothelial nitric-oxide synthase impairment.

226 f vascular remodelling by over-expression of endothelial nitric oxide synthase in the fat pad of the

227 ogenitor cells, transiently transfected with endothelial nitric oxide synthase, in patients with PAH

228 b nitric oxide production and muscle phospho-endothelial nitric oxide synthase increased in a stepwis

229 a, tumor necrosis factor-alpha, IL-6, IL-10, endothelial nitric oxide synthase, inducible nitric oxid

230 onstitutive isoforms, including neuronal and endothelial nitric oxide synthase, inducible nitric oxid

231 We identify the endogenous endothelial nitric oxide synthase inhibitor ADMA as a bi

232 D-serine coactivation of NMDA receptors and endothelial nitric oxide synthase is involved in astrocy

233 synthase and that the vasodilatory effect of endothelial nitric oxide synthase is likely mediated by

234 cose delivery in FcgammaRIIB(-/-) mice or in endothelial nitric oxide synthase knock-in mice with pho

235 m wild type mice than those in the aortas of endothelial nitric oxide synthase knock-out mice.

236 By using endothelial nitric oxide synthase knockout (eNOSKO) mice

237 cently, we and others reported that diabetic endothelial nitric oxide synthase knockout (eNOSKO) mice

238 Finally, treatment of diabetic endothelial nitric oxide synthase knockout mice with sel

239 AR3 antagonist, affects development of DN in endothelial nitric oxide synthase-knockout db/db mice.

240 Mice lacking a functional endothelial nitric oxide synthase (KO, NOS3(-/-) ) and w

241 vasodilator dysfunction was due to decreased endothelial nitric oxide synthase levels and impaired sm

242 SIRT1-mediated signalling through Akt, the endothelial nitric oxide synthase mediated pathway, regu

243 ssion in both ApoE(-/-) and WT EPCs, whereas endothelial nitric oxide synthase messenger RNA expressi

244 2(.-) anions, whether derived from uncoupled endothelial nitric oxide synthase, nicotinamide adenine

245 f the vascular endothelial growth factor-Akt-endothelial nitric oxide synthase-nitric oxide-cGMP path

246 in db/db mice through a tetrahydrobiopterin/endothelial nitric oxide synthase/nitric oxide pathway.

247 ysfunction was associated with uncoupling of endothelial nitric oxide synthase (NOS) activity seconda

248 beta3-AR colocalized with caveolin-3, endothelial nitric oxide synthase (NOS) and neuronal NOS

249 enerative phase, during hyperoxia, defective endothelial nitric oxide synthase (NOS) produces reactiv

250 atechol-O-methyl transferase (COMT(-/-)) and endothelial nitric oxide synthase (Nos3(-/-)) knockout m

251 structurally intact cells, is controlled by endothelial nitric oxide synthase (NOS3) and is crucial

252 tion of apelin, apelin receptor (APLNR), and endothelial nitric oxide synthase (NOS3) in HA adaptatio

253 We hypothesized that uncoupled endothelial nitric oxide synthase (NOS3) through upregul

254 opterin (BH(4)) is an essential cofactor for endothelial nitric oxide synthase (NOS3), decreased bioa

255 Diabetes was induced in hypertensive endothelial nitric oxide synthase (Nos3)-deficient mice

256 Expression of endothelial nitric-oxide synthase (NOS3) was not altered

257 etary nitrate improves insulin resistance in endothelial nitric oxide synthase null mice, and multipl

258 erated DN model, STZ-induced diabetes in the endothelial nitric oxide synthase-null (eNOS(-/-)) mice.

259 lial nitric oxide synthase-dependent because endothelial nitric oxide synthase-null mice displayed an

260 hibitory domain (residues 595-639) in bovine endothelial nitric oxide synthase on enzyme activity and

261 ited downstream signaling pathways involving endothelial nitric oxide synthase or prostanoid producti

262 nction was manifested by decreased levels of endothelial nitric oxide synthase (P< .005) and Kruppel-

263 oronary arterioles, (2) heart phosphorylated endothelial nitric oxide synthase (p-eNOS/eNOS) protein,

264 The phosphorylated endothelial nitric oxide synthase (PeNOS)/endothelial ni

265 lencing CSE by siRNA significantly increased endothelial nitric oxide synthase phosphorylation at thr

266 stored nitric oxide production and decreased endothelial nitric oxide synthase phosphorylation at thr

267 bular adiponectin dose-dependently increased endothelial nitric oxide synthase phosphorylation but ha

268 selectively inhibited Bcl-xL expression and endothelial nitric oxide synthase phosphorylation but in

269 ulin resistance, including decreased Akt and endothelial nitric oxide synthase phosphorylation in the

270 tion of protein kinase C and loss of Akt and endothelial nitric oxide synthase phosphorylation occurr

271 tion-induced cardiac GLUT4 translocation and endothelial nitric oxide synthase phosphorylation were b

272 or kappaB activation, an increase in Akt and endothelial nitric oxide synthase phosphorylation, and a

273 ce K(+) channels (K(Ca)3.1 and K(Ca)2.3) and endothelial nitric oxide synthase, produces additive ton

274 ssion of inducible nitric oxide synthase and endothelial nitric oxide synthase, production of nitric

275 ylated endothelial nitric oxide synthase and endothelial nitric oxide synthase protein levels and nit

276 In conclusion, a lack of endothelial nitric oxide synthase resulted in the develo

277 ease in VEGFR2 phosphorylation and increased endothelial nitric oxide synthase Ser(1177) phosphorylat

278 longevity-associated variant-BPIFB4 restores endothelial nitric oxide synthase signaling, rescues end

279 or, and L-citrulline (L-Cit) is converted to endothelial nitric oxide synthase substrate, L-arginine.

280 nism that involves the activation of the Akt-endothelial nitric oxide synthase survival pathway, and

281 nism that involves the activation of the Akt-endothelial nitric oxide synthase survival pathway, and

282 of VE-cadherin, KDR, von Willebrand factor, endothelial nitric oxide synthase, the lack of CD45, CD1

283 udies, these effects alter the expression of endothelial nitric oxide synthase, the stability of athe

284 Seven to 50 million endothelial nitric oxide synthase-transfected endothelia

285 Metanx ingredients counteract endothelial nitric oxide synthase uncoupling and oxidati

286 link between the transport of l-arginine and endothelial nitric oxide synthase uncoupling in hyperten

287 that is associated with vascular remodeling, endothelial nitric oxide synthase uncoupling, decreased

288 Metanx treatment counteracted endothelial nitric oxide synthase uncoupling, inducible

289 Caffeine down-regulated endothelial nitric oxide synthase, vascular endothelial

290 observe any relevant changes in the vascular endothelial nitric oxide synthase vasodilatory response,

291 er-reporter episomal transfection assays for endothelial nitric oxide synthase, VE-cadherin, and vWF

292 the islet capillary dilation is modulated by endothelial nitric oxide synthase via complementary sign

293 endothelial progenitor cells overexpressing endothelial nitric oxide synthase was tolerated hemodyna

294 Both retinal protein and mRNA expression of endothelial nitric oxide synthase were decreased by twof

295 e 4, vascular endothelial growth factor, and endothelial nitric oxide synthase were remarkably higher

296 endent genes, cyclooxygenase 2 and inducible endothelial nitric oxide synthase, were assessed in peri

297 scular cell adhesion molecule-1 (VCAM-1) and endothelial nitric oxide synthase, whereas PDEs had sign

298 nd on both the production of nitric oxide by endothelial nitric-oxide synthase, which ascorbate is kn

299 ndomethacin (Indo; 5 microm) nor blockade of endothelial nitric oxide synthase with N(G)-nitro-L-argi

300 Shear stress-dependent stimulation of endothelial nitric oxide synthase within the femoral art